Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT, banking stocks not in favor
Fri, 5 Oct 01:30 pm

The Indian equity markets continued to trade in the negative territory, albeit in a range bound manner during the post noon trading session. While stocks from the FMCG and auto spaces have managed to find some gains, other sectoral indices are trading weak led by information technology and banking stocks.

The Sensex today is trading lower by about 140 points (down 0.7%), while the NSE-Nifty is trading lower by about 40 points (0.7%). Stocks from the midcap and smallcap spaces are also trading weak with the BSE Mid Cap and BSE Small Cap indices down by about 0.8% and 1.1% respectively. The rupee is trading at 51.71 to the US dollar.

Stocks of pharmaceutical companies are trading weak led by Pfizer, Novartis and Abbott India. As per a leading financial daily, the commerce department is going in a big way to grab US$ 30-40 bn worth of the overseas generics market as patents held by multinational companies set to expire over the next three years. Under its recently launched 'Brand India Pharma' campaign, the commerce department wants to hard-sell Indian generics in difficult but promising markets where the focus will be on credibility, quality, availability and affordability of Indian medicines. Reportedly, India's pharma exports stood at $13 billion in 2011. The country produces 20% of the generic medicines of the world and accounts for about 70% of medicines supplied to poor countries through humanitarian agencies. Recently, the commerce department led two delegations comprising Indian pharma companies like Dr. Reddy's, Lupin, Mylan and Nectar, to Japan and Indonesia under the Brand India Pharma Campaign to explore opportunities there.

Stocks of real estate and construction companies are trading weak led by IVRCL, Gammon India andUnity Infraprojects. After declining sharply in yesterday's trading session, the stock of midcap construction company IVRCL is trading down by about 5% today as well. Declines in the stock are seemingly on the back of reports of the Essel Group selling its 12.27% stake in IVRCL yesterday. It may be recollected that the Essel Group had expressed interest in increasing its stake in IVRCL, after buying into the company about six months ago. In fact, the buzz surrounding the stock of IVRCL was of a possible hostile takeover bid leading it to gain significantly.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT, banking stocks not in favor". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.